Low PE, High ROCE Small-Cap Pharma Stock Hits Fresh All-Time High After FSSAI Approves Plant-Based Vitamin D3 Ingredient for Indian Food Market

On Monday, Indian benchmark indices traded higher in early trade. As of the latest available trade, the Nifty 50 index was up 155.90 points, or 0.64 per cent, at 24,426.75. Amid the positive market sentiment, Fermenta Biotech share price jumped 13.48 per cent to Rs 389.25 after the company announced a key regulatory approval from the Food Safety and Standards Authority of India (FSSAI).

The stock trades at a PE of 17.3, significantly below the industry average of 35.1, while delivering a healthy ROCE of 20.4 per cent. Trading activity also remained robust, with volume at 18.4 lakh shares compared with the 30-day average of 1.28 lakh shares

FSSAI Approves Plant-Based Vitamin D3

Fermenta Biotech Limited has received FSSAI approval for its Vitamin D3 (Cholecalciferol), Plant Source (VITADEE Green®) as an approved ingredient for health supplements, nutraceuticals and food products in India.

The approval allows Indian food and supplement manufacturers to incorporate VITADEE Green® into fortified staple foods, beverages, dietary supplements and nutraceutical formulations. According to the company, the approval provides a domestically manufactured, regulatory-approved plant-based Vitamin D3 solution for India's large vegetarian population.

Expands Opportunity in Nutrition Market

The company stated that Vitamin D deficiency continues to remain a major public health concern in India due to urban lifestyles, indoor work environments and limited sun exposure.

With this approval, Fermenta expects to strengthen its position in food fortification initiatives by offering a sustainable, scalable and affordable plant-source Vitamin D3 developed under an Indian process patent. The company added that the approval supports wider adoption of plant-based nutrition ingredients while contributing to the Government's Make in India initiative.
Also Read - Low-Debt Pharmaceutical Stock Falls 9% After Company Discloses Customs Department Investigation Against Senior Official

Management Commentary

Commenting on the development, Prashant Nagre, Managing Director, said: "Vitamin D deficiency remains a widespread public health concern in India, and the demand for sustainable nutrition continues to grow rapidly. The FSSAI approval allows us to bring VITADEE Green® directly to Indian food fortification and nutraceutical manufacturers, helping bridge the nutrition gap for the country's large population. As one of the first Indian companies to develop and patent a sustainable, scalable and affordable plant-source Vitamin D3 process, we are well placed to tackle the deficiency at a national level. Developed and manufactured in India, VITADEE Green® also supports the Make in India vision by offering a self-reliant domestic option for Indian formulators. Crucially, VITADEE Green® offers Indian formulators the superior D3 form in a fully plant-sourced format, rather than the Vitamin D2 they have often had to settle for. This is a meaningful step in our commitment to delivering differentiated, science-validated and sustainable solutions that create lasting value for our customers and for society."

About Fermenta Biotech

Fermenta Biotech Limited is engaged in the development and manufacturing of Vitamin D3, active pharmaceutical ingredients (APIs) and specialty nutritional ingredients. The company supplies its products to customers across the pharmaceutical, food fortification, animal nutrition and nutraceutical industries in domestic as well as international markets.

The company is one of the leading manufacturers of Vitamin D3 solutions and focuses on science-backed, sustainable and scalable nutrition products. Through its patented VITADEE Green® technology, Fermenta aims to expand access to plant-based Vitamin D3 solutions while supporting India's growing preventive healthcare and food fortification ecosystem.

What are your thoughts on Fermenta Biotech's FSSAI approval for VITADEE Green®? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.